厄贝沙坦氢氯噻嗪早期联合美托洛尔治疗老年心力衰竭临床观察被引量：1

下载PDF

导出

摘要目的观察厄贝沙坦氢氯噻嗪早期联合美托洛尔治疗老年心力衰竭的临床效果。方法选取2014年1月—2014年12月我院收治的68例老年心力衰竭患者为研究对象,将其随机分为观察组与对照组,观察组给予厄贝沙坦氢氯噻嗪联合美托洛尔治疗,对照组给予常规治疗联合美托洛尔治疗,比较2组患者的临床疗效。结果观察组总有效率高于对照组(P<0.05);且治疗后,观察组心力衰竭的分级(NYHA)与脑钠肽(BNP)水平比较,差异均有统计学意义(P<0.05)。结论厄贝沙坦氢氯噻嗪早期联合美托洛尔治疗老年心力衰竭临床效果显著,值得在临床上推广。

作者郭伟

机构地区社旗县妇幼保健院

出处《基层医学论坛》 2016年第6期762-763,共2页 The Medical Forum

关键词心力衰竭老年厄贝沙坦氢氯噻嗪美托洛尔

分类号 R541.6 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献4

1顾德明.厄贝沙坦氢氯噻嗪联合美托洛尔治疗老年重症心力衰竭的疗效研究[J].实用心脑肺血管病杂志,2014,22(5):16-17. 被引量：58
2陈志刚,张永莉,刘辉,岳兵.厄贝沙坦氢氯噻嗪早期联合美托洛尔治疗老年心力衰竭76例[J].中国老年学杂志,2013,33(2):399-400. 被引量：51
3卢世文,李峥,柳明波.老年慢性充血性心力衰竭患者下呼吸道感染的病原菌分布及药敏分析[J].中华医院感染学杂志,2015,25(1):55-57. 被引量：9
4郭俊,李维,刘易珏,陈阵,艾芬.血浆儿茶酚抑素水平对慢性心力衰竭患者预后的影响[J].华中科技大学学报（医学版）,2014,43(2):209-212. 被引量：5

二级参考文献33

1高润霖,胡大一.心血管病诊治新进展[M].北京:人民军医出版社,2011.178-183.
2van Der Harst P, Voors AA,van Gilst WH, et al. Statins in the treatment of chronic heart failure :biological and clinical considerations [ J. Card- iovasc Res ,2006 ;71 ( 3 ) :443-54.
3Rosen D, Decaro MV, Graham MG. Evidence-based treatment of chronic heart failure [ J 1. Compr Ther,2007 ;33 ( 1 ) :2-17.
4孙云飞.厄贝沙坦氢氯噻嗪治疗高血压临床观察[J].健康必读,2011;7(3):27-8.
5Adauceanu A, Ducki C, Virion JM, et al. Extracellular matrix turnover and inflammatory markers independently predict functional status and outcome in chronic heart failure [ J 1. J Card Fail,2008;14 (6) :467.
6Schulz TJ,Westermann D,Isken F,et al.Activation of mitochondrial energy metabolism protects against cardiac failure[J].Aging(Albany NY),2010,2(11):843.
7Dickstein K, Cohen-Solal A,Filippatos G, et al. ESC guide- lines for the diagnosis and treatment of acute and chronic heart {allure 2008 : the Task Force {or the diagnosis and treat- ment of acute and chronic heart failure 2008 of the European Society of CardiQ[ogy. Developed in Soc;.ety o{ Intensive Care Medicine (ESICM) [J]. Eur J Heart Fail, 2008,10 (10) : 933- 989.
8Mahapatra N R, Mahata M, Mahata S K, et al. The ehro- mogranin A fragment eatestatin: specificity, potency and mechanism to inhibit exocytotic secretion of multiple cate cholamine storage vesicle co-transmitters [J]. J Hypertens, 2006,24(5) : 895-904.
9Rao F, Wen G, Gayen J R, et al. Catecholamine release-inhibi- tory peptide catestatin (chromogranin A(352-372)) : natural- ly occurring amino acid variant G[y364Ser causes pro-found changes in human autonomic activity and alters risk for hy- pertension [J]. Circulation,2007,115 (17) :2271-2281.
10Gheorghiade M, De Luca L, Fonamw G C, et al. Pathophysio logic targets in the early phase of acute heart failure syn- dromes [J]. Am J Cardiol,2005,96(6A) :llG-17G.